Please login to the form below

Not currently logged in
Email:
Password:

benign prostatic hyperplasia

This page shows the latest benign prostatic hyperplasia news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use

Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use

Urovant aims to investigate the drug’s use in overactive bladder (OAB), as well as another trial in OAB patients with benign prostatic hyperplasia, plus a third trial in patients with

Latest news

More from news
Approximately 2 fully matching, plus 33 partially matching documents found.

Latest Intelligence

  • Interview: Giovanni Recordati Interview: Giovanni Recordati

    The company also has long expertise in urology. “ We are currently rolling out a new drug for the treatment of benign prostatic hyperplasia and will soon be starting the last phase

  • Interview: Jorge Gallardo, Almirall Interview: Jorge Gallardo, Almirall

    The year's sales evolution has benefited from the launches of new products Silodyx (for benign prostatic hyperplasia, licence from Recordati) and Conbriza  (for osteoporosis, in co-promotion with Pfizer) in

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Life Brands Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics